News & Updates

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 1-15 April 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A Hong Kong territory-wide study has found that despite improved glycaemic outcomes and device reimbursement, use of continuous glucose monitoring systems (CGMS) and/or automated insulin delivery (AID) systems remains suboptimal in patients ≤18 years old with type 1 diabetes (T1D), particularly among adolescents, alluding to barriers beyond cost.

Maternal obesity appears to increase bile acid (BA) levels in breast milk, which may have implications for neonatal digestion, maturation, and health.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and liraglutide, improves histologic outcomes in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) without compromising safety, reports a Singapore study.

A real-world analysis shows effective glycaemic control with the MiniMed 780G (MM780G) system—an advanced automated insulin delivery (AID) system with bolus autocorrection every 5 min—in users on no-bolus days, with more users achieving glycaemic goals when the recommended optimal settings (ROS) were used.

A hybrid obesity care that combines physician-directed glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment and lifestyle coaching via a mobile health app yields meaningful and sustained improvements in weight and metabolic parameters in a real-world setting, as shown in a local study.

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) offers a minimally invasive resolution of symptoms in patients with a suspicion of insulinomas and has a favourable safety profile relative to surgery, according to a study. However, its long-term efficacy warrants further investigation.

Patients with mild autonomous cortisol secretion (MACS) may experience poor sleep quality comparable to those with Cushing syndrome (CS), reports a study. Notably, sleep impairment appears to be more common among younger women with higher clinical MACS severity.

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.